Drug updated on 11/5/2024
| Dosage Form | Capsule (oral; 100 mg) |
| Drug Class | Kinase inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adults with intermediate or highrisk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 109 /L
Latest News
Summary
- This summary is based on the review of one systematic review(s)/meta-analysis(es). [1]
- Pacritinib is less effective than ruxolitinib as a first-line treatment for reducing spleen volume, but it shows effectiveness in second-line treatment after ruxolitinib exposure.
- Fedratinib and momelotinib have comparable efficacy to ruxolitinib for spleen volume reduction in first-line therapy.
- Pacritinib is noted for its second-line effectiveness after ruxolitinib, while no second-line data is provided for fedratinib or momelotinib.
- There is no safety information available in the reviewed documents.
- There is no population types or subgroups information available in the reviewed documents.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Vonjo (pacritinib) Prescribing Information. | 2023 | CTI BioPharma Corp., Seattle WA |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Efficacy and tolerability of Janus kinase inhibitors in myelofibrosis: a systematic review and network meta-analysis | 2021 | Blood Cancer Journal |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. | 2022 | Journal of the National Comprehensive Cancer Network |